Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
- Strong revenue growth in the base business of 7% for the full year 2023
- Double-digit revenue growth in several clinical areas
- Robust pipeline of M&A and professional lab services opportunities
- 5.6% increase in quarterly dividend
- Estimated full year 2024 guidance with a net revenues increase of 1.1% to 2.1%
- Fourth quarter revenues down 1.9%
- Full year revenues down 6.4% from 2022
- Adjusted diluted EPS down 12.5% from 2022
Quest Diagnostics' financial results highlight a complex fiscal landscape. The decline in COVID-19 testing revenues is notable, dropping by approximately 80% in Q4 and 85% for the full year, reflecting the pandemic's transition into an endemic phase and the resultant normalization of testing demand. However, the company's base business revenues increased by 7.1% over the full year, indicating resilience and potential growth areas outside of pandemic-related services.
The increase in reported diluted EPS by 95.4% in Q4 and the projection for both reported and adjusted diluted EPS for 2024 suggest optimism about cost management and profitability. Despite this, the full year reported diluted EPS decreased by 6% and adjusted diluted EPS decreased by 12.5%, which may raise concerns about the company's ability to maintain profitability amid changing market conditions.
Investors should consider the dividend increase as a positive signal of the company's commitment to shareholder returns, marking continuous annual increases since 2011. However, a critical observation is the decline in cash provided by operations by 25.9% for the full year, which could indicate challenges in operational efficiency or cash flow management.
From a market perspective, Quest Diagnostics' performance reflects broader trends in the healthcare diagnostics sector. The shift away from COVID-19 testing revenue is expected across the industry, as is the focus on expanding core diagnostic services and strategic investments in areas like oncology and genetic testing. These fields are growing due to technological advancements and an increased emphasis on personalized medicine.
The company's strategic investment in minimal residual disease testing aligns with the industry's move towards more sophisticated diagnostic capabilities, which could open new revenue streams and strengthen its competitive position. Additionally, the growth strategy involving mergers and acquisitions, as well as new partnerships with health systems, is a common approach to expanding service offerings and market reach.
Quest Diagnostics' guidance for 2024 suggests cautious optimism, with projected revenue growth and earnings. This outlook may be influenced by the company's ability to capitalize on its growth strategy and adapt to the decreasing demand for COVID-19 testing.
Quest Diagnostics' financial results also provide insight into the evolving landscape of healthcare services. The increase in base business revenues suggests a successful pivot towards traditional diagnostic services and a recovery from the pandemic's impact. The growth in clinical areas such as advanced cardiometabolic, prenatal and hereditary genetics and neurology indicates a strategic alignment with emerging healthcare needs and a focus on high-growth potential markets.
The company's operating income saw a significant increase in Q4, but a decrease over the full year, highlighting the importance of operational efficiency and the potential impact of fluctuating service demands. The operating income as a percentage of net revenues also decreased, which could suggest margin pressures that may need to be addressed.
Quest Diagnostics' anticipated revenue growth and earnings for 2024, along with its commitment to dividends, present a company positioning itself for sustainable growth in the post-pandemic era. The focus on innovation and strategic investments, particularly in areas like minimal residual disease testing, may provide a competitive edge and drive long-term growth.
- Fourth quarter revenues of
$2.29 billion 1.9% from 2022 - Fourth quarter reported diluted earnings per share ("EPS") of
$1.70 95.4% from 2022; and adjusted diluted EPS of$2.15 8.6% from 2022 - Fourth quarter base business revenues of
$2.25 billion 4.7% from 2022 - Fourth quarter COVID-19 testing revenues of
$37 million 79.8% from 2022 - Full year revenues of
$9.25 billion 6.4% from 2022 - Full year reported diluted EPS of
$7.49 6.0% from 2022; and adjusted diluted EPS of$8.71 12.5% from 2022 - Full year base business revenues of
$9.03 billion 7.1% from 2022 - Full year COVID-19 testing revenues of
$223 million 84.7% from 2022 - Full year 2024 reported diluted EPS expected to be between
$7.69 $7.99 $8.60 $8.90
"We delivered strong revenue growth in our base business of
Mr. Davis continued: "Our guidance for 2024 reflects a return to overall revenue growth while balancing the earnings tailwinds and headwinds we see for the year. Looking beyond 2024, we are well positioned to deliver our long-term financial outlook to drive mid-single digit revenue growth and high-single digit earnings growth. Finally, I'm grateful to our dedicated Quest colleagues who bring our purpose to life every day, working together to create a healthier world, one life at a time."
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||
2023 | 2022 | Change | 2023 | 2022 | Change | ||||||
(dollars in millions, except per share data) | |||||||||||
Reported: | |||||||||||
Net revenues | $ 2,288 | $ 2,333 | (1.9) % | $ 9,252 | $ 9,883 | (6.4) % | |||||
Base business revenues (a) | $ 2,251 | $ 2,149 | 4.7 % | $ 9,029 | $ 8,429 | 7.1 % | |||||
COVID-19 testing revenues | $ 37 | $ 184 | (79.8) % | $ 223 | $ 1,454 | (84.7) % | |||||
Diagnostic information services revenues | $ 2,221 | $ 2,265 | (2.0) % | $ 8,976 | $ 9,609 | (6.6) % | |||||
Revenue per requisition | (3.5) % | (5.9) % | |||||||||
Requisition volume | 1.9 % | (0.6) % | |||||||||
Organic requisition volume | 1.4 % | (1.0) % | |||||||||
Operating income (b) | $ 267 | $ 135 | 98.2 % | $ 1,262 | $ 1,428 | (11.6) % | |||||
Operating income as a percentage of net revenues (b) | 11.7 % | 5.8 % | 5.9 % | 13.6 % | 14.5 % | (0.9) % | |||||
Net income attributable to Quest Diagnostics (b) | $ 192 | $ 101 | 91.3 % | $ 854 | $ 946 | (9.7) % | |||||
Diluted EPS (b) | $ 1.70 | $ 0.87 | 95.4 % | $ 7.49 | $ 7.97 | (6.0) % | |||||
Cash provided by operations | $ 527 | $ 334 | 58.0 % | $ 1,272 | $ 1,718 | (25.9) % | |||||
Capital expenditures | $ 72 | $ 147 | (51.6) % | $ 408 | $ 404 | 0.9 % | |||||
Adjusted (b): | |||||||||||
Operating income | $ 338 | $ 330 | 2.1 % | $ 1,457 | $ 1,742 | (16.3) % | |||||
Operating income as a percentage of net revenues | 14.8 % | 14.2 % | 0.6 % | 15.8 % | 17.6 % | (1.8) % | |||||
Net income attributable to Quest Diagnostics | $ 245 | $ 229 | 6.9 % | $ 994 | $ 1,181 | (15.9) % | |||||
Diluted EPS | $ 2.15 | $ 1.98 | 8.6 % | $ 8.71 | $ 9.95 | (12.5) % | |||||
(a) | Excludes COVID-19 testing. |
(b) | For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below. |
Dividend Increased
Quest Diagnostics' Board of Directors has authorized a
Guidance for Full Year 2024
We estimate full year 2024 guidance as follows:
Low | High | ||
Net revenues | |||
Net revenues increase | 1.1 % | 2.1 % | |
Reported diluted EPS | |||
Adjusted diluted EPS | |||
Cash provided by operations | Approximately | ||
Capital expenditures | Approximately | ||
Note on Non-GAAP Financial Measures
As used in this press release the term "reported" refers to measures under accounting principles generally accepted in
Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.
Conference Call Information
Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on February 1, 2024 until midnight Eastern Time on February 15, 2024, by phone at 800-934-9421 for domestic callers and 203-369-3391 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest annually serves one in three adult Americans and half the physicians and hospitals in
Forward Looking Statements
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.
This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.
ADDITIONAL TABLES FOLLOW
Quest Diagnostics Incorporated and Subsidiaries Consolidated Statements of Operations For the Three and Twelve Months Ended December 31, 2023 and 2022 (in millions, except per share data) (unaudited) | |||||||
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Net revenues | $ 2,288 | $ 2,333 | $ 9,252 | $ 9,883 | |||
Operating costs and expenses and other operating income: | |||||||
Cost of services | 1,552 | 1,575 | 6,199 | 6,450 | |||
Selling, general and administrative | 407 | 563 | 1,642 | 1,874 | |||
Amortization of intangible assets | 27 | 39 | 108 | 120 | |||
Other operating expense, net | 35 | 21 | 41 | 11 | |||
Total operating costs and expenses, net | 2,021 | 2,198 | 7,990 | 8,455 | |||
Operating income | 267 | 135 | 1,262 | 1,428 | |||
Other income (expense): | |||||||
Interest expense, net | (40) | (32) | (152) | (138) | |||
Other income (expense), net | 10 | 6 | 20 | (55) | |||
Total non-operating expense, net | (30) | (26) | (132) | (193) | |||
Income before income taxes and equity in earnings of equity method investees | 237 | 109 | 1,130 | 1,235 | |||
Income tax (expense) benefit | (40) | 4 | (248) | (264) | |||
Equity in earnings of equity method investees, net of taxes | 8 | 3 | 26 | 44 | |||
Net income | 205 | 116 | 908 | 1,015 | |||
Less: Net income attributable to noncontrolling interests | 13 | 15 | 54 | 69 | |||
Net income attributable to Quest Diagnostics | $ 192 | $ 101 | $ 854 | $ 946 | |||
Earnings per share attributable to Quest Diagnostics' common stockholders: | |||||||
Basic | $ 1.72 | $ 0.89 | $ 7.59 | $ 8.10 | |||
Diluted | $ 1.70 | $ 0.87 | $ 7.49 | $ 7.97 | |||
Weighted average common shares outstanding: | |||||||
Basic | 112 | 113 | 112 | 116 | |||
Diluted | 113 | 115 | 113 | 118 | |||
Quest Diagnostics Incorporated and Subsidiaries Consolidated Balance Sheets December 31, 2023 and 2022 (in millions, except per share data) (unaudited) | |||
December 31, 2023 | December 31, 2022 | ||
Assets | |||
Current assets: | |||
Cash and cash equivalents | $ 686 | $ 315 | |
Accounts receivable, net | 1,210 | 1,195 | |
Inventories | 190 | 192 | |
Prepaid expenses and other current assets | 286 | 196 | |
Total current assets | 2,372 | 1,898 | |
Property, plant and equipment, net | 1,816 | 1,766 | |
Operating lease right-of-use assets | 602 | 585 | |
Goodwill | 7,733 | 7,220 | |
Intangible assets, net | 1,166 | 1,092 | |
Investment in equity method investees | 135 | 132 | |
Other assets | 198 | 144 | |
Total assets | $ 14,022 | $ 12,837 | |
Liabilities and Stockholders' Equity | |||
Current liabilities: | |||
Accounts payable and accrued expenses | $ 1,359 | $ 1,396 | |
Current portion of long-term debt | 303 | 2 | |
Current portion of long-term operating lease liabilities | 153 | 153 | |
Total current liabilities | 1,815 | 1,551 | |
Long-term debt | 4,410 | 3,978 | |
Long-term operating lease liabilities | 503 | 489 | |
Other liabilities | 876 | 812 | |
Redeemable noncontrolling interest | 76 | 77 | |
Stockholders' equity: | |||
Quest Diagnostics stockholders' equity: | |||
Common stock, par value | 2 | 2 | |
Additional paid-in capital | 2,320 | 2,295 | |
Retained earnings | 8,825 | 8,290 | |
Accumulated other comprehensive loss | (14) | (21) | |
Treasury stock, at cost; 51 shares as of both December 31, 2023 and 2022 | (4,826) | (4,673) | |
Total Quest Diagnostics stockholders' equity | 6,307 | 5,893 | |
Noncontrolling interests | 35 | 37 | |
Total stockholders' equity | 6,342 | 5,930 | |
Total liabilities and stockholders' equity | $ 14,022 | $ 12,837 | |
Quest Diagnostics Incorporated and Subsidiaries Consolidated Statements of Cash Flows For the Twelve Months Ended December 31, 2023 and 2022 (in millions) (unaudited) | |||
Twelve Months Ended December 31, | |||
2023 | 2022 | ||
Cash flows from operating activities: | |||
Net income | $ 908 | $ 1,015 | |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 439 | 437 | |
Provision for credit losses | 1 | 3 | |
Deferred income tax (benefit) provision | (49) | 1 | |
Stock-based compensation expense | 77 | 77 | |
Other, net | 41 | 66 | |
Changes in operating assets and liabilities: | |||
Accounts receivable | (15) | 246 | |
Accounts payable and accrued expenses | (55) | (149) | |
Income taxes payable | (2) | (31) | |
Other assets and liabilities, net | (73) | 53 | |
Net cash provided by operating activities | 1,272 | 1,718 | |
Cash flows from investing activities: | |||
Business acquisitions, net of cash acquired | (611) | (144) | |
Capital expenditures | (408) | (404) | |
(Increase) decrease in investments and other assets, net | (42) | 5 | |
Net cash used in investing activities | (1,061) | (543) | |
Cash flows from financing activities: | |||
Proceeds from borrowings | 2,592 | — | |
Repayments of debt | (1,844) | (2) | |
Purchases of treasury stock | (275) | (1,408) | |
Exercise of stock options | 72 | 123 | |
Employee payroll tax withholdings on stock issued under stock-based compensation plans | (28) | (28) | |
Dividends paid | (314) | (305) | |
Distributions to noncontrolling interest partners | (57) | (73) | |
Other financing activities, net | 14 | (39) | |
Net cash provided by (used in) financing activities | 160 | (1,732) | |
Net change in cash and cash equivalents and restricted cash | 371 | (557) | |
Cash and cash equivalents and restricted cash, beginning of period | 315 | 872 | |
Cash and cash equivalents and restricted cash, end of period | $ 686 | $ 315 | |
Cash paid during the period for: | |||
Interest | $ 134 | $ 156 | |
Income taxes | $ 317 | $ 283 | |
Notes to Financial Tables | |
1) | The computation of basic and diluted earnings per common share is as follows: |
Three Months Ended | Twelve Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
(in millions, except per share data) | |||||||
Amounts attributable to Quest Diagnostics' common stockholders: | |||||||
Net income attributable to Quest Diagnostics | $ 192 | $ 101 | $ 854 | $ 946 | |||
Less: Earnings allocated to participating securities | — | — | 4 | 4 | |||
Earnings available to Quest Diagnostics' common stockholders - basic and diluted | $ 192 | $ 101 | $ 850 | $ 942 | |||
Weighted average common shares outstanding - basic | 112 | 113 | 112 | 116 | |||
Effect of dilutive securities: | |||||||
Stock options and performance share units | 1 | 2 | 1 | 2 | |||
Weighted average common shares outstanding - diluted | 113 | 115 | 113 | 118 | |||
Earnings per share attributable to Quest Diagnostics' common stockholders: | |||||||
Basic | $ 1.72 | $ 0.89 | $ 7.59 | $ 8.10 | |||
Diluted | $ 1.70 | $ 0.87 | $ 7.49 | $ 7.97 | |||
2) | The following tables reconcile reported GAAP results to non-GAAP adjusted results: |
Three Months Ended December 31, 2023 | |||||||||||
(dollars in millions, except per share data) | |||||||||||
Operating income | Operating | Income tax | Equity in | Net income | Diluted EPS | ||||||
As reported | $ 267 | 11.7 % | $ (40) | $ 8 | $ 192 | $ 1.70 | |||||
Restructuring and integration charges (a) | 11 | 0.5 | (2) | — | 9 | 0.07 | |||||
Other (b) | 33 | 1.4 | (6) | — | 27 | 0.23 | |||||
Amortization expense | 27 | 1.2 | (8) | — | 19 | 0.17 | |||||
ETB | — | — | (2) | — | (2) | (0.02) | |||||
As adjusted | $ 338 | 14.8 % | $ (58) | $ 8 | $ 245 | $ 2.15 | |||||
Twelve Months Ended December 31, 2023 | |||||||||||
(dollars in millions, except per share data) | |||||||||||
Operating | Operating | Income tax | Equity in | Net income | Diluted EPS | ||||||
As reported | $ 1,262 | 13.6 % | $ (248) | $ 26 | $ 854 | $ 7.49 | |||||
Restructuring and integration charges (a) | 43 | 0.5 | (10) | — | 33 | 0.29 | |||||
Other (b) | 44 | 0.5 | (8) | — | 36 | 0.31 | |||||
Gains and losses on investments (c) | — | — | (1) | 3 | 2 | 0.02 | |||||
Amortization expense | 108 | 1.2 | (28) | — | 80 | 0.70 | |||||
ETB | — | — | (11) | — | (11) | (0.10) | |||||
As adjusted | $ 1,457 | 15.8 % | $ (306) | $ 29 | $ 994 | $ 8.71 | |||||
Three Months Ended December 31, 2022 | |||||||||||
(dollars in millions, except per share data) | |||||||||||
Operating | Operating | Income tax | Equity in | Net income | Diluted EPS | ||||||
As reported | $ 135 | 5.8 % | $ 4 | $ 3 | $ 101 | $ 0.87 | |||||
Restructuring and integration charges (a) | 51 | 2.2 | (12) | — | 39 | 0.34 | |||||
Other (b) | 21 | 0.9 | (20) | — | 1 | 0.01 | |||||
Gains and losses on investments (c) | — | — | (2) | 3 | 1 | 0.01 | |||||
Quest for Health Equity costs (d) | 84 | 3.6 | (22) | 62 | 0.53 | ||||||
Amortization expense | 39 | 1.7 | (10) | — | 29 | 0.25 | |||||
ETB | — | — | (4) | — | (4) | (0.03) | |||||
As adjusted | $ 330 | 14.2 % | $ (66) | $ 6 | $ 229 | $ 1.98 | |||||
Twelve Months Ended December 31, 2022 | |||||||||||
(dollars in millions, except per share data) | |||||||||||
Operating | Operating | Income tax | Equity in | Net income | Diluted EPS | ||||||
As reported | $ 1,428 | 14.5 % | $ (264) | $ 44 | $ 946 | $ 7.97 | |||||
Restructuring and integration charges (a) | 88 | 0.9 | (22) | — | 66 | 0.56 | |||||
Other (b) | 13 | 0.1 | (19) | — | (6) | (0.05) | |||||
Gains and losses on investments (c) | — | — | (11) | 12 | 31 | 0.26 | |||||
Quest for Health Equity costs (d) | 93 | 0.9 | (24) | — | 69 | 0.59 | |||||
Amortization expense | 120 | 1.2 | (31) | — | 89 | 0.74 | |||||
ETB | — | — | (14) | — | (14) | (0.12) | |||||
As adjusted | $ 1,742 | 17.6 % | $ (385) | $ 56 | $ 1,181 | $ 9.95 | |||||
(a) | For both the three and twelve months ended December 31, 2023, the pre-tax impact represents costs primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. For both the three and twelve months ended December 31, 2022, the pre-tax impact represents costs primarily associated with workforce reductions, systems conversions and integration costs incurred in connection with further restructuring and integrating our business. The following table summarizes the pre-tax impact of restructuring and integration charges on our consolidated statements of operations: |
Three Months Ended | Twelve Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
(dollars in millions) | |||||||
Cost of services | $ 4 | $ 19 | $ 16 | $ 32 | |||
Selling, general and administrative | 7 | 32 | 27 | 56 | |||
Operating income | $ 11 | $ 51 | $ 43 | $ 88 | |||
(b) | For both the three and twelve months ended December 31, 2023, the pre-tax impact primarily represents a |
Three Months Ended | Twelve Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
(dollars in millions) | |||||||
Cost of services | $ — | $ — | $ — | $ 2 | |||
Selling, general and administrative | (2) | — | 5 | — | |||
Other operating expense, net | 35 | 21 | 39 | 11 | |||
Operating income | $ 33 | $ 21 | $ 44 | $ 13 | |||
(c) | For all periods presented, the pre-tax impact primarily represents gains and losses associated with changes in the carrying value of our strategic investments. The following table summarizes the pre-tax impact of gains and losses on investments on our consolidated statement of operations: |
Three Months Ended | Twelve Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
(dollars in millions) | |||||||
Other income (expense), net | $ — | $ — | $ — | $ 30 | |||
Equity in earnings of equity method investees, net of taxes | $ — | $ 3 | $ 3 | $ 12 | |||
(d) | For both the three and twelve months ended December 31, 2022, the pre-tax impact represents the costs associated with donations, contributions and other financial support through Quest for Health Equity, recorded in selling, general and administrative expenses. |
(e) | For restructuring and integration charges, gains and losses on investments, Quest for Health Equity costs, other items and amortization expense, income tax impacts, where recorded, were primarily calculated using combined statutory income tax rates of |
3) | For the three and twelve months ended December 31, 2023, we repurchased 2.0 million shares of our common stock for |
4) | The outlook for adjusted diluted EPS represents management's estimates for the full year 2024 before the impact of special items. Further impacts to earnings related to special items may occur throughout 2024. Additionally, the amount of ETB is dependent upon employee stock option exercises and our stock price, both of which are difficult to predict. The following table reconciles our 2024 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS: |
Low | High | ||
Diluted EPS | $ 7.69 | $ 7.99 | |
Restructuring and integration charges (a) | 0.17 | 0.17 | |
Amortization expense (b) | 0.84 | 0.84 | |
ETB | (0.10) | (0.10) | |
Adjusted diluted EPS | $ 8.60 | $ 8.90 |
(a) | Represents estimated pre-tax charges of |
(b) | Represents estimated pre-tax amortization expenses of |
.
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-reports-fourth-quarter-and-full-year-2023-financial-results-provides-guidance-for-full-year-2024-increases-quarterly-dividend-5-6-to-0-75-per-share-302049923.html
SOURCE Quest Diagnostics
FAQ
What was the percentage change in fourth quarter revenues for Quest Diagnostics (DGX)?
What was the change in reported diluted EPS for Quest Diagnostics (DGX) in the fourth quarter?
What was the change in adjusted diluted EPS for Quest Diagnostics (DGX) in the fourth quarter?
What was the percentage change in full year revenues for Quest Diagnostics (DGX)?
What was the change in reported diluted EPS for Quest Diagnostics (DGX) for the full year?
What was the change in adjusted diluted EPS for Quest Diagnostics (DGX) for the full year?
What is the ticker symbol for Quest Diagnostics?
What is the expected range for full year 2024 reported diluted EPS for Quest Diagnostics (DGX)?
What is the expected range for full year 2024 adjusted diluted EPS for Quest Diagnostics (DGX)?
